SMV5: Dr. Michael Triplett on closing a 9 figure exit before Series A.

Written By Jeff (J.D.) Davids
SMV Podcast Triplett Episode Image.png

SMV5: Myonexus Therapeutics CEO Dr. Michael Triplett shares how they closed a 9 figure exit event prior to securing Series A financing.

This episode of the SmartMoney Ventures Podcast features Dr. Michael Triplett, CEO of Myonexus Therapeutics who, along with co-founder Dr. Louise Rodino-Klapac, successfully completed a 9 figure exit event before securing Series A financing.

The story illustrates how successful tech transfer and strategic positioning resulted in the establishment of a new Gene Therapy Center of Excellence creating over 100 new jobs while transforming Muscular Dystrophy patient treatments. 

Prior to co-founding Myonexus, Michael held leadership positions at Procter & Gamble, Battelle Memorial Institute and Ventaira Pharmaceuticals among others. Dr. Triplett holds both a bachlor’s degree and a Ph.D. in Chemical Engineering from THE Ohio State University graduating Summa Cum Laude.    

In this episode, you will learn:

  1. How to get a 9 figure exit before your Series A financing

  2. How Technology Transfer is transforming the Heartland Region

  3. Why resilience is a big part of entrepreneurial psychology

  4. Sage advice for technical & scientific founders

  5. How a Gene Therapy Center of Excellence was established in Central Ohio

Jeff (J.D.) Davids
Previous

SMV6: Tim Schigel on how he found Lightning in a Bottle with ShareThis.
Next

SMV4: Ketos’ Meena Sankaran: From Engineer to CEO raising $30 Million